Coronary artery disease in patients with type 1 diabetes mellitus

Česká verzia

Authors: J. Charvát
Authors place of work: Interní klinika 2. LF UK a FN v Motole, Praha
Published in the journal: Kardiol Rev Int Med 2014, 16(2): 131-133
Category: Internal Medicine

Summary

The presence of cardiovascular disease, and especially coronary artery disease, in patients with type 1 diabetes mellitus impairs life expectancy. Hyperglycaemia, which increases oxidative stress, is the key pathophysiological factor. Coronary artery calcifications, the presence of cardiac autonomic neuropathy and diabetic nephropathy are significantly associated with coronary artery disease manifestations. Likewise, the hypoglycaemic episodes significantly increase the cardiovascular risk. Based on the clinical trial outcomes, there is evidence showing that good compensation of type 1 diabetes from the time of its manifestation can significantly reduce the occurrence and progression of macrovascular complications, including coronary artery disease. The correction of hypertension and dyslipidaemia is also beneficial.

Key words:
type 1 diabetes mellitus – hyperglycaemia – coronary artery disease

Zdroje

1. Preis SR, Hwang SJ, Coady S et al. Trends in all‑cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in Framingham Heart Study,1950 to 2005.Circulation 2009; 119: 1728– 1735. doi: 10.1161/ CIRCULATIONAHA.108.829176.

2. Miller RG, Secrest AM, Sharma RK et al. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012; 61: 2987– 2992. doi: 10.2337/ db11– 1625.

3. Schnell O, Standl E. Diabetes and cardiovascular disease. Current status of trials. Clin Res Cardiol Suppl 2010; 5 (Suppl 1): S27– S34.

4. Koivisto VA, Stevens LK, Mattock M et al. Cardiovascular disease and its risk factors in IDDM in Europe, EURODIAB IDDM Complications Study Group. Diabetes Care 1996; 19: 689– 697.

5. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre‑diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88– 136.

6. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a „casual“ antioxidant therapy. Diabetes Care 2003; 26: 1589– 1596.

7. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes and cardiovascular events. Diabetes Care 2010; 33: 1389– 1394. doi: 10.2337/ dc09- 2082.

8. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7: 260– 273. doi: 10.1177/ 1479164110383723.

9. Witte DR, Tesfaye S, Chaturvedi N et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48: 164– 171.

10. Muhr D, Mollenhauer U, Ziegler AG et al. Autoantibodies to sympathetic ganglia, GAD, or tyrosine phosphatase in lonterm IDDM with and without ECG‑based autonomic neuropathy. Diabetes Care 1997; 20: 1009– 1012.

11. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risk. Diabetes Care 2011; 34 (Suppl 2): S132– S137. doi: 10.2337/ dc11– s220.

12. Tuomilehto J, Borch‑ Johnsen K, Molarius A et al. Incidence of cardiovascular disease in Type 1 (insulin‑dependent) diabetes subjects with and without diabetic nephropathy in Finland. Diabetologia 1998; 41: 784– 790.

13. Lurbe E, Redon J, Kesani A et al. Increase of noctural blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797– 805.

14. Prince CT, Secrest AM, Mackey RH et al. Pulse wave analysis and prevalent cardiovascular disease in type 1 diabetes. Atherosclerosis 2010; 213: 469– 474. doi: 10.1016/ j.atherosclerosis.2010.08.080.

15. Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima‑ media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294– 2303

16. Snell‑ Bergeon JK, Hokanson JE, Jensen L et al. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care 2003; 26: 2923– 2928.

17. Turek SJ, Hastings SM, Sun JK et al. Sexual Dysfunction as a Marker of Cardiovascular Disease in Males With 50 or More Years of Type 1 Diabetes. Diabetes care 2013; 36: 3222– 3226. doi: 10.2337/ dc13– 0294.

18. American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013; 36 (Suppl 1): S11– S66. doi: 10.2337/ dc13– S011.

19. Geluk CA, Dikkers R, Kors JA et al. Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST‑T changes on the resting ECG: an evaluation study. BMC Cardiovasc Disord 2007; 7: 19.

20. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643– 2653.

21. Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized open label study. Diabet Res Clin Pract 2013; 100: e55– e58. doi: 10.1016/ j.diabres.2013.01.020.

22. Ceriello A, Novials A, Ortega E et al. Glucagon‑ Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 diabetes. Diabetes Care 2013; 36: 2346– 2350. doi: 10.2337/ dc12- 2469.